GENINCODE PLC LS -01 Market Cap ($5.28 Million)
Market Cap & Net Worth: GENINCODE PLC LS -01 (9PL)
GENINCODE PLC LS -01 market cap. GENINCODE PLC LS -01 (F:9PL) has a market capitalization of $5.28 Million (€4.52 Million) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #28413 globally and #2445 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENINCODE PLC LS -01's stock price €0.01 by its total outstanding shares 753041137 (753.04 Million). Also see 9PL cash flow conversion for how efficiently the company converts equity into cash flow.
GENINCODE PLC LS -01 Market Cap History (2021–2026)
GENINCODE PLC LS -01 market cap history from 2021 to 2026. Data shows change from $315.18 Million to $5.28 Million (-56.77% CAGR). Check GENINCODE PLC LS -01 stock price for real-time trading data and today's change.
GENINCODE PLC LS -01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENINCODE PLC LS -01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 9PL net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.44x
GENINCODE PLC LS -01's market cap is 5.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $315.18 Million | $1.15 Million | -$4.14 Million | 273.12x | N/A |
| 2022 | $71.31 Million | $1.43 Million | -$5.56 Million | 49.87x | N/A |
| 2023 | $50.18 Million | $2.16 Million | -$7.02 Million | 23.23x | N/A |
| 2024 | $37.86 Million | $2.70 Million | -$4.43 Million | 14.02x | N/A |
| 2025 | $16.73 Million | $3.08 Million | -$5.71 Million | 5.44x | N/A |
Competitor Companies of 9PL by Market Capitalization
Companies near GENINCODE PLC LS -01 in the global market cap rankings as of November 1, 2026. Also see total assets of GENINCODE PLC LS -01 for a full breakdown of the balance sheet.
Key companies related to GENINCODE PLC LS -01 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of GENINCODE PLC LS -01 (2021–2026)
Market capitalization of GENINCODE PLC LS -01 from 2021 to today. Between 2021 and today, GENINCODE PLC LS -01's market cap moved from $315.18 Million to $ 5.28 Million, with a yearly change of -56.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.28 Million | -68.42% |
| 2025 | €16.73 Million | -55.81% |
| 2024 | €37.86 Million | -24.56% |
| 2023 | €50.18 Million | -29.63% |
| 2022 | €71.31 Million | -77.37% |
| 2021 | €315.18 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 1st, 2026 the market cap of GENINCODE PLC LS -01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.28 Million USD |
| MoneyControl | $5.28 Million USD |
| MarketWatch | $5.28 Million USD |
| marketcap.company | $5.28 Million USD |
| Reuters | $5.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENINCODE PLC LS -01
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of fa… Read more